Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy.

ABSTRACT:

Background

Our objective was to assess real-world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy.

Methods

We used the Symphony Dataverse to study patients receiving mavacamten between May 25, 2022 and June 30, 2024. Safety outcomes were prespecified.

Results

We included 2440 patients and 18 494 mavacamten dispenses (63% women, median age 66 years [interquartile range {IQR}, 55-73]). Patients were followed for a median of 3037.0 days (IQR, 2808-3221) before mavacamten initiation and for 240 days (IQR, 117-407) on mavacamten. Atrial fibrillation or flutter (AF/AFL) at baseline were present in 536 (22%) of patients, whereas new-onset AF/AFL requiring therapy occurred in 125 patients (5%) and

SUBMITTER: Mahana I 

PROVIDER: S-EPMC12684520 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature